Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Approval

Clinical Trials

FDA Approves Juvmo, the First Selective D1/D5 Agonist for Parkinson’s

Approval clears the way for an October 2026 U.S. launch, with payer coverage and real‑world safety set to shape how the drug is used.

FDA Approves Regeneron’s Pasatru for Adults With FOP

FDA Panel Rejects Deramiocel Cardiac Claim After Lancet Publishes HOPE‑3 Results

Regulators Move to Strip Approval of Tavneos After Trial Misconduct and Liver Safety Signals

Cellular Intelligence Takes Global Rights to Novo Nordisk’s Parkinson’s Cell Therapy

FDA Rejects Replimune’s Melanoma Virus Therapy Again for Insufficient Evidence

For Third Time, FDA Rejects Aldeyra’s Dry-Eye Drug Reproxalap Over Efficacy

FDA Approves Lynkuet, a Nonhormonal Pill for Menopausal Hot Flashes

EU Approves Donanemab as Second Alzheimer’s Antibody Under Tight Conditions

FDA Rejects Aldeyra's Reproxalap NDA for Dry Eye Disease Over Efficacy Issues

Neumora’s Depression Drug Fails to Meet Goals in Key Phase 3 Trial